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Abstract
Background: Tamsulosin is an inhibitory factor of alpha-adrenergic receptors that is
used for relieving of the clinical symptoms and management of acute urinary retention.
Objective: The aim of this study was to evaluate the effects of tamsulosin on the
endocrine axis and testicular tissue in adult male rats.
Materials andMethods: In this experimental study, 30 adult male Wistar rats (weighing
250-300 gr) were divided into three groups: 1) control (received distilled water), 2)
experimental 1 (received 0.2 mg/kg/day tamsulosin) and 3) experimental 2 (received
0.4 mg/kg/day tamsulosin) through oral gavage for 28 days. Serum hormones level
and testicular histopathology were evaluated at the end of the experiment.
Results: In this study, the testicular weight decreased significantly in the experimental
groups compared to the control group. A significant decrease was seen in testicular
weight (p = 0.004) and the number of Leydig cells in tamsulosin-treated groups (p =
0.012). Tamsulosin improved the hormone profile in experimental groups. Also, higher
dose of tamsulosin significantly changed the number of Leydig, spermatogonia cells,
the thickness of germinal layer, and the diameter of the seminiferous tubules.
Conclusion: Results showed that using tamsulosin, possibly reduces the testosterone
concentration through adrenergic axis system and in turn has destructive effects on
proliferative activity of germ cells.
Key words: Tamsulosin, Seminiferous tubules, Histopathology, Rat, Testis.
How to cite this article: Kohestani Y, Kohestani B, Shirmohamadi Z, Faghani M. “Effect of tamsulosin on testis histopathology and serum hormones in adult rats:




Sciences, Faculty of Medicine,





Tel: (+98) 911 3910626
Email:
mfaghani2000@gmail.com
Received 29 January 2019
Revised 12 October 2019
Accepted 14 January 2020
Production and Hosting by
Knowledge E
Kohestani et al. This article
is distributed under the terms
of the Creative Commons
Attribution License, which
permits unrestricted use and
redistribution provided that




International Journal of Reproductive BioMedicine Kohestani et al.
1. Introduction
Benign prostatic hyperplasia (BPH) is considered
as one of the most common diseases in men that
can lead to lower urinary tract symptoms (LUTS).
The prevalence of BPH significantly increases
with age, so that, some studies show that the
disease prevalence increases by up to 80% with
aging (1, 2). Based on researches in Europe,
United States, and Asia, old men have a higher
risk factor for the onset and progression of the
clinical BPH (1-5). In addition, prostate volume
increases with age, so that according to Krimpen
and Baltimore longitudinal studies on aging, the
prostate hypertrophy rate is 2-2.5% annually (1, 6,
7). Therefore, prostate hypertrophy could be a risk
factor for LUTS progression. The larger prostate
is associated with benign prostatic enlargement
(BPE). This enlargement increases the risk of BPH,
urinary retention, and the need for prostate surgery
(8).
LUTS are treated by alpha 1-adrenergic receptor
blocking drugs and 5-alpha-reductase inhibitor (9,
10). Alpha1 receptors are predominantly present in
the stromal tissue of prostate, prostatic urethra, and
urinary bladder (11). In other words, the relaxation of
the smooth muscles of the prostate and bladder is
reduced LUTS in patientswith BPH (11). In addition, it
is reported that alpha-adrenergic receptor function
depends on multiple effectors systems such as
multiple G proteins (12). These proteins activate a
series of cellular mechanisms that alter the levels
of cyclic AMP and intra- and extra cellular Ca++ (13).
Of note, Alpha adrenergic receptor agonist might
activate these mechanisms (12).
Tamsulosin (Flomax) is considered as one of the
selective antagonists for α1A and α1D adrenergic
receptors. One of its side effects is disturbance in
the male fertility system (13). There are several
effective factors on male fertility reduction,
including important congenital malformations
of the genitourinary system, infectious diseases,
genetic disorders, immunologic factors and
endocrine axes disorders, painful or difficult
urination, abnormal ejaculation, and back pain (14).
However, idiopathic cause was found in 60-70%of
cases in male infertility (15).
Besides, most researchers, on the other hand,
have investigated the effect of tamsulosin in the
treatment of BPH (16). Researchers have reported
that the use of tamsulosin relaxes the prostate
and bladder neck muscles and increases bladder
emptying (17). They have focused on tamsulosin
therapeutic effects that reduce urinary retention
and prostate hyperplasia; however, the probable
cytotoxic effects of it on testicular tissue have
not been considered yet. It is worth nothing that
increasing old population inmost societies resulted
in higher incidence of BPH and LUTS. Therefore,
to reduce the symptoms of patients with BPH and
LUTS, tamsulosin is considered as a safe drug (16,
18) and is prescribed routinely; however, its effect
on endocrine axis and histology of testicular tissue
has not been fully studied. Thus, the present study
was aimed to evaluate the effect of tamsulosin
on serum concentration of male hormones and
histopathology of the testicular tissue.
2. Materials and Methods
2.1. Animals and treatment
Thirty adult male Wistar rats (weighing 250-300
gr) were purchased from the Pasteur Institute of
Iran. Rats were kept under standard conditions
for one week for adaption to new environment
(temperature of 21 ± 2°C and 12 hr light/darkcycle).
The control group (N = 10) received distilled water
(solvent for tamsulosin), the experimental group
1 received 0.2 mg/kg/day tamsulosin, and the
experimental group 2 received 0.4 mg/kg/day
tamsulosin based on human dosage (19, 20).
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Animals were gavaged with 1 ml distilled water or
tamsulosin solution for 28 consecutive days (19).
2.2. Blood sampling and testis weight
measurement
After 28 days, the rats were anesthetized and
then sacrificed with diethyl ether. The blood
samples were obtained directly from their hearts,
and then the left testis was removed and weighed.
2.3. Preparing the tissue samples
In order to examine the testis histological
changes, the left testis was fixed for seven days
in a Modified Davidsons Fluid (MDF) solution
containing 30% formaldehyde, 15% ethanol, 5%
glacial acetic acid, and 50% distilled water. The
testes were then washed with PBS solution and
cut into smaller pieces. The MDF-fixed testes were
dehydrated and embedded in paraffin.
Sections measuring 5 µm were prepared and
at least five slides from each testis were stained
with Heiden Hain Azan for histopathological
evaluation. This was performed according to
the routine tissue-staining methods. In order
to evaluate the testis tissue histopathological
changes, four slices were assessed from each
mouse. Five microscopic fields from each slide
were observed at 400× magnification using a
standard light microscope (Olympus, Japan).
Spermatogonia, Sertoli, and Leydig cells were
counted using the light microscope, and the
images were prepared by a digital camera (BX
51 Japan) calibrated with a hemocytometer slide
share attached to the microscope. Germinal
epithelium area, seminiferous tubules diameter,
and number of seminiferous tubules and interstitial
cells were measured using the Image J 1.44P
software (National institute of Health, USA).
2.4. Serum hormones level analysis
After anesthesia, the rats’ blood samples were
immediately obtained directly from their heart
to determine the serum level of testosterone,
LH, and FSH at the end of the study. Then, the
blood samples were centrifuged at 3000 rpm
for 20 min. Hormones level was measured using
the Testosterone ELISA kits (Abcam, ab108666),
EKU05694 Rat Luteinizing Hormone (LH) ELISA
kit (ZellBio Germany), and EKU04249 Rat Follicle
Stimulating Hormone (FSH) ELISA kit (ZellBio
Germany). All reagents, standards, and samples
were prepared according to the instructions
presented in the kit.
2.5. Ethical consideration
Animals were maintained in accordance with the
ethical standards approved by the Animal Care
Committee of Guilin University of Medical Sciences
(IR.GUMS.REC.1398.388).
2.6. Statistical analysis
The results were presented with mean and
standard deviation. Data were analyzed using the
Statistical Package for the Social Sciences, version
18.0, SPSS Inc, Chicago, Illinois, USA (SPSS), and p
< 0.05 was considered as significant. ANOVA and
Tukey’s test were used to compare the parametric
parameters (testicular weight, testosterone,
LH and FSH concentrations, and number of
spermatogonia, Leydig, and Sertoli cells). Non-
parametric test (Kruskal-Wallis H) was used to
compare the histopathological grades (diameter
of cells and the area of germinal epithelium) and
the non-parametric test (Mann-whitney U) with
modification of pairwise comparisons (to control
the first type error) was used if the results test was
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significant. Kolmogorov-smirnov test was used to
determine the normal distribution of data.
3. Results
A statistically significant difference was detected
between the testes weight in all groups (p =
0.004), but there were no significant differences
between the control and experimental groups 1 (p
= 0.98) (Table I). However, significant differences
were observed in the testes weight of the control
and experimental group 2 (p = 0.008) and the
experimental groups 1 and 2 as well (p = 0.012).
Our findings revealed that tamsulosin
significantly decreased the plasma concentration
of testosterone in comparison with the control (p
= 0.0001) (Table I). Moreover, testosterone level
decreased more in the experimental group 2
compared to the experimental group 1 (p = 0001)
(Table I; Figure 1). Of note, tamsulosin significantly
increased the FSH level in the experimental groups
(p = 0.009).
The spermatogenesis was evaluated in germinal
epithelium through spermatogonia cell numbers.
It showed a significant decrease in the numbers
of spermatogonia across all groups (p = 0.0001).
In addition, there was a significant difference
in the number of spermatogonia between
the experimental groups in dose-dependent
manner of tamsulosin (Table II). Furthermore,
areas of reproductive epithelium remarkably
reduced in the experimental groups (p = 0.0001).
Interestingly, some vacuoles were observed in
germinal epithelium especially in the experimental
group 2 (Figure 1).
Table I. Comparison of testes weight and serum testosterone concentrations in the control group and the groups treated by
tamsulosin (n = 10)
``````````̀Parameters
Groups
Control (mean ± SD) Experimental 1 (mean ± SD) Experimental 2 (mean ± SD) P-value
Testicle weight (gr) 1.00 ± 0.15 0.99 ± 0.15𝑏 0.80 ± 0.10𝑎 0.004
Testosterone (ng/ml) 1.05 ± 0.21 0.81 ± 0.09𝑐 0.60 ± 0.10𝑏 0.0001
LH (ng/ml) 0.194 ± 0.048 0.172 ± 0.051 0.155 ± 0.039 0.186
FSH (ng/ ml) 0.202 ± 0.048 0.254 ± 0.042 0.304 ± 0.057𝑎 0.0001
Mean ± SD, one-way ANOVA, and post-hoc tests; 𝑎Significant between the control group and the experimental group 2;
𝑏Significant between the experimental groups 1 and 2; 𝑐Significant between the control group and the experimental group
1; Control: The group that received distilled water; Experimental 1: The group that received 0.2 mg/kg/day tamsulosin; and
Experimental 2: The group that received 0.4 mg/ kg/day tamsulosin. LH: Luteinizing hormone; FSH: Follicle-stimulating
hormone; SD: standard deviation
Table II. Comparison of number of spermatogonia, area of reproductive epithelium, and seminiferous tubules diameter in the
different groups (n = 10)
``````````̀Parameters
Groups
Control (mean ± SD) Experimental 1 (mean ± SD) Experimental 2 (mean ± SD) P-value
Spermatogonia number 37.52 ± 4.14 32.43 ± 6.06𝑎 23.03 ± 4.88𝑏 0.001
Area of reproductive
epithelium
36661.65 ± 5706.4 30009.12 ± 8005.49𝑎 15344.34 ± 4164.54𝑏 0.001
Seminiferous tubules
diameter
51498.95 ± 6597.87 45517.13 ± 6214.75𝑎 20983.23 ± 6679.39𝑏 0.001
Sertoli cell number 17.168 ± 4.060 16.588 ± 4.543 15.153 ± 5.048 0.603
Leydig cell number 16.513 ± 5.112 14.193 ± 3.701 11.165 ± 1.072𝑐 0.012
Mean ± SD, one-way ANOVA, and post-hoc tests, 𝑎Significant between the control group and the experimental group 1(0.2
mg/kg/day); 𝑏Significant between the experimental groups 1 and 2; 𝑐Significant between the control group and the experimental
group 2; Control: The group that received distilled water; Experimental 1: The group that received 0.2 mg/kg/day tamsulosin;
and Experimental 2: The group that received 0.4 mg/kg/day tamsulosin. SD: standard deviation
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Figure 1. Microscopic image of testicular tissue sections in different groups (at 400x magnification; scale bar: 20 microns; and
staining method: Heiden Hain Azan). (A) Control group (the group that received distilled water): The testicle tissue is normal in
terms of the number of spermatogonia, the thickness of reproductive epithelium, and the diameter of the seminiferous tubules.
(B) Experimental group 1 (the group that received 0.2 mg/kg/day tamsulosin): According to the testicular tissue in this group,
spermatogonia, reproductive epithelial thickness, and the number of spermatogonia reduced. (C) Experimental group 2 (the group
that received 0.4 mg/kg/day tamsulosin): The testicular tissue in this group shows a very severe reduction in the thickness of
reproductive epithelium and its degeneration and a significant decrease in spermatogonia.
4. Discussion
The present study showed that tamsulosin
resulted in pathological changes in testis and the
secretion of testosterone in male rats. In addition,
it is suggested that tamsulosin could inhibit
androgenesis process. The serum testosterone
level was decreased significantly among the
experimental groups (p < 0.05), which indicates
the strong impact of higher dose of tamsulosin on
androgenesis. It is suggested that the tamsulosin
exerts its function on the activity of gonadotropin-
releasing hormone under the influence of
norepinephrine by alpha-adrenergic receptors.
Norepinephrine, as a neurotransmitter that is
secreted from adrenergic neurons, has a significant
impact on adrenergic receptors, especially alpha
receptors. Also, these adrenergic neurons can
target gonadotropin-releasing hormone (14, 21,
22). Furthermore, norepinephrine can release the
LH-releasing hormone.
According to Selvage’s findings, prazosin
and adrenergic receptors inhibitor reduced
the production of LH-releasing hormone in the
hypothalamus and resulted in LH decrease (23).
In other words, this axis is able to influence the
secretion of testosterone through the inhibition
of LH. In addition, some studies have shown that
the alternative releasing of LHRH is modulated by
adrenergic neurons, particularly norepinephrine,
via alpha1-adrenergic receptors (22, 24).
Alpha-blockers are usually used as the first
choice of treatment for patients suffering from LUTS
because the safety and effectiveness of these have
been confirmed in many randomized studies (17,
25, 26).
Androgens exert their effects on prostate
proliferation by binding and activating the
androgen receptors. Anti-androgens competitively
inhibit the binding of the receptors by agonists.
When anti-androgens are combined to their
receptors, they, therefore, don’t bind to DNA and
transcription would be inhibited (27).
On the other hand, based on Gotkas and
coworker’s study, the advantage of taking single
dose of tamsulosin compared to the rest of α1-
adrenoceptor antagonist is not convincing enough
for this medicine to be used in all patients (20).
Therefore, it seems that clinicians routinely use
different doses of tamsulosin depending on the
severity of the disease. In addition, α-blockers
often influence the secretion of testosterone.
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According to our results, taking 0.2 and 0.4
mg/kg of tamsulosin for 28 days significantly
decreased the testosterone concentration and
disturbed the testicular tissue histology in the
experimental groups. This may be described by the
harmful effects of tamsulosin on the gonadotropin-
hypothalamic axis and Leydig cells. Our finding
was confirmed by the reduction of the numbers of
Leydig cells between the experimental groups (p =
0.009).
Some studies used 0.4 mg/kg of tamsulosin to
treat BPH based on the severity of the disease
and did not consider the side effects of tamsulosin
in reducing spermatogonia and Leydig cells (26,
28). Of note, our study showed that tamsulosin
at a dose of 0.2 mg/kg can also significantly
reduce the number of spermatogonia. and Leydig
cells. Significant reduction of androgens with a
0.2 mg/kg of tamsulosin can sufficiently reduce
androgens for the desirable therapeutic effect.
To prevent the side effects of tamsulosin, it is
recommended to use a lower dose of 0.2 mg/kg
for the treatment of LUTS.
Our study revealed a significant decrease
in the number of spermatogonia, the areas of
reproductive epithelium, and the diameter of
seminiferous tubules in the experimental groups (p
< 0.001), which indicates the destructive effect of
tamsulosin in the testicular tissue. In addition, our
study showed that there were many vacuoles in
germinal epithelium in experimental groups 1 and
2 compared to the control group that may indicate
tissue damage in the germinal epithelium. Our data
are consistent with the results of previous studies
on the dose-dependent use of this drug. Beltagy
and coworkers found that the treatment with
tamsulosin hydrochloride had more harmful side
effects than finasteride on rats, which leads to the
disturbances in prostatic, testicular function, and
neurotransmitters indices (29). Besides, they also
reported that combined treatment of finasteride
with tamsulosin hydrochloride has lower side
effects than tamsulosin hydrochloride alone.
In another study, researchers combined the
tamsulosin with non- α-blockers such as Omega
3 fatty acid and the results were fantastic. They
reported that this co-treatment had better clinical
results (30). In another study, drugs combination
therapy was used to reduce the deleterious effects
of tamsulosin. They showed that the combination
of three drugs LDD175, tamsulosin, and finasteride
is more effective in the treatment of BPH patients
because some patients are ressistnt to individual
administration of these drugs (31). On In another
study, the researchers observed a significant
decrease in the number, mobility, activity, and
survival of the epididymal sperm after tamsulosin
injection, especially at higher doses. Higher doses
of drug results in a significant decrease in
testosterone levels, testes and body weight,
diameter of seminiferous tubules, and number
of Leydig cells (32). It seems that tamsulosin
has destructive effects on testis tissue, imbalance
hormones level and infertility. Therefore, using low
dose of this drug alongside the application of other
proper antagonist drugs is recommended.
5. Conclusion
Finally, according to the results of this study,
the secretion of testosterone hormone reduced
after the administration of tamsulosin and could
possibly have a significant effect on hypothalamic-
hypophysial axis. Testosterone impacts the
activity of the gonadotrophin-releasing hormone,
which is itself influenced by norepinephrine
and adrenergic receptors. Considering the AUA
Guideline and ejaculatory dysfunction at higher
doses of tamsulosin, it is better to avoid using
higher doses of tamsulosin to prevent its adverse
side effects on testicular tissue. It is revealed
that histopathological changes of testicular tissue
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resulted in the reduction of hormone levels.
Therefore, it is suggested that a combination
therapy with other drugs could probably reduce
the harmful side effects of tamsulosin.
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